Rekha Patel

Rekha Patel

Auto-generated profile, based on publicly available information

Rekha Patel

Alexion, AstraZeneca Rare Disease

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Journal of Chromatography B
Verified
Journal Article
Closed access
YKYekaterina Kori
Yekaterina Kori
RPRekha Patel
Rekha Patel
ANAlyssa Neill
Alyssa Neill
HLHongcheng Liu
Hongcheng Liu

1 February 2016 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Open access
CNC. Nikam
C. Nikam
RPR. Patel
R. Patel
MSM. Sadani
M. Sadani
KAK. Ajbani
K. Ajbani
MKM. Kazi
M. Kazi
CRC. Rodrigues
C. Rodrigues
BACKGROUND: Although line-probe assays (LPAs) are promising, little research has been conducted to elucidate the true nature of indeterminate LPA results or assess the ability of these assays to perform on a wide range of clinical samples. OBJECTIVE: To evaluate the performance of the commercially available GenoType® MTBDRplus LPA against conventional BACTEC™ MGIT™ 960 culture and drug susceptibility testing (DST) among 308 pulmonary tuberculosis (PTB) and 32 extra-pulmonary TB samples. RESULTS: Invalid LPA results (defined as those with a missing Mycobacterium tuberculosis identification band) were obtained for 18 PTB samples, which were excluded from further analysis. The sensitivity and specificity of the MTBDRplus assay for multidrug-resistant TB, based upon the results obtained for the remaining 322 samples, was respectively 95.2% and 95.1%. Of 290 PTB samples, 40 (13.7%) were indeterminate on LPA (defined as the absence of both wild-type and corresponding mutation bands) for isoniazid (INH) and/or rifampicin (RMP), and were further evaluated by pyrosequencing (PSQ). Contrary to standard LPA interpretation, INH and RMP susceptibility were confirmed by both DST and PSQ in respectively 7.5% (3/40) and 27.5% (11/40) of indeterminate samples. CONCLUSION: PSQ was found to be a valuable and rapid technique to resolve discrepancies in LPA test results that were not interpretable.

13 October 2024 in mAbs
Verified
Journal Article
Open access
PTPaul Tamburini
Paul Tamburini
DPDennis Vestergaard Pedersen
Dennis Vestergaard Pedersen
DDDenise Devore
Denise Devore
JCJosh Cone
Josh Cone
RPRekha Patel
Rekha Patel
JHJeffrey Hunter
Jeffrey Hunter
The bispecific antibody tarperprumig (ALXN1820) was developed as a treatment option for diseases involving dysregulated complement alternative pathway (AP) activity that could be administered in small volumes, either subcutaneously or intravenously. Tarperprumig incorporates a C-terminal variable domain of a heavy chain only antibody (VHH) that binds properdin (FP) connected via a flexible linker to an N-terminal VHH that binds human serum albumin (HSA). The purified bispecific VHH antibody exhibits an experimental molecular weight average of 27.4 kDa and can be formulated at > 100 mg/mL. Tarperprumig binds tightly to FP and HSA with sub-nanomolar affinity at pH 7.4 and can associate simultaneously with FP and HSA to form a ternary complex. Tarperprumig potently and dose-dependently inhibits to completion in vitro AP-dependent complement C5b-9 formation, AP-dependent hemolysis, and the AP deposition of C3, FP and C9. X-ray crystallography revealed that the isolated FP-binding VHH recognizes the thrombospondin repeat 5 domain of FP, thereby preventing FP from binding to the AP convertase owing to severe steric hindrance. Tarperprumig cross-reacts with cynomolgus monkey FP and serum albumin. In summary, tarperprumig exhibits properties tailored for subcutaneous administration and is currently in clinical development for the treatment of complement AP-related disorders.

10 December 2021 in FASEB BioAdvances
Verified
Journal Article
Open access
PDF file
RPRekha S. Patel
Rekha S. Patel
RRRea Rupani
Rea Rupani
SISabrina Impresso
Sabrina Impresso
ALAshley Lui
Ashley Lui
NPNiketa Patel
Niketa Patel
Ovarian cancer is the deadliest malignant disease in women. Protein Kinase C delta (PRKCD; PKCδ) is serine/threonine kinase extensively linked to various cancers. In humans, PKCδ is alternatively spl...